Treating Breast Cancer Screening with Personalized Risk Assessments for Women
NCT02620852 · RecruitingThis study looks at how women can be screened for breast cancer based on their personal risk factors instead of using a standard method for everyone. It compares traditional annual mammograms with a more personalized schedule that considers each woman's history and risk. The goal is to find a better way to screen for breast cancer that reduces unnecessary stress and treatment while still catching any potential issues early.
Locations and contact
This trial is running at 11 locations in the United States. 9 of them are currently recruiting.
United States11 locations · 9 recruiting
- TopLine MD AllianceMiami, FloridaRecruiting
- University of Alabama at BirminghamBirmingham, AlabamaRecruiting
- University of California DavisSacramento, CaliforniaRecruiting
- University of California IrvineIrvine, CaliforniaRecruiting
- University of California Los AngelesLos Angeles, CaliforniaRecruiting
- University of California San DiegoSan Diego, CaliforniaRecruiting
- University of California San FranciscoSan Francisco, CaliforniaRecruiting
- University of ChicagoChicago, IllinoisRecruiting
- Weill Cornell MedicineNew York, New YorkRecruiting
- Edith Sanford Breast CenterSioux Falls, South DakotaActive Not Recruiting
- Louisiana State UniversityNew Orleans, LouisianaActive Not Recruiting
Who can join
This trial is for women aged 30 to 74 living in the United States. It is open to anyone who identifies as female. Women with a past history of breast cancer or certain other conditions cannot participate. The trial team will confirm each person's eligibility.
What happens during the trial
Participants will be divided into two groups. One group will receive annual mammograms and basic health advice. The other group will have a personalized screening schedule based on their individual risk factors, including family history and genetic tests. Everyone will complete a health questionnaire and provide a saliva sample for testing.
The trial team
The University of California, San Francisco leads this trial, with support from several organizations, including the National Cancer Institute and the Patient-Centered Outcomes Research Institute. Dr. Laura Esserman is the principal investigator.
Important dates
The study started on August 31, 2016, and is expected to complete by September 1, 2026. It is currently enrolling new participants.
Additional information
The trial's ID number is NCT02620852. It is not focused on a specific phase, and there are no FDA-regulated drugs involved. The study aims to include around 100,000 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →